Skip to main content
PMC home page
Molecular Medicine logoLink to Molecular Medicine
. 1995 Nov;1(7):795–805.

Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation.

K Gijbels 1, S Brocke 1, J S Abrams 1, L Steinman 1
PMCID: PMC2230023  PMID: 8612202

Abstract

BACKGROUND: We previously demonstrated the local production of the pleiotropic cytokine interleukin-6 (IL-6) in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE), an animal model for the human disease multiple sclerosis. MATERIALS AND METHODS: To assess the role of IL-6 in autoimmune CNS inflammation, we administered neutralizing antibodies to IL-6 in the EAE model. Their effect was examined at the clinical and histopathological level. Levels of administered antibody and IL-6 bioactivity were followed in serum and cerebrospinal fluid (CSF). RESULTS: Systemically administered antibodies penetrated into the fluid CSF in animals in which EAE was induced. Administration of anti-IL-6 reduced the development of actively induced as well as adoptively transferred EAE and was associated with increased levels of IL-6 activity in the CSF and to a lesser extent in the serum. Anti-IL-6 was still effective when given 1 day before the onset of disease signs in adoptively transferred EAE. The disease-reducing effect of anti-IL-6 was also reflected at the pathological level by the absence of inflammatory infiltrates in the CNS. CONCLUSIONS: Our study indicates that IL-6 plays an important role in autoimmune CNS inflammation. However, due to the complex nature of the in vivo interactions of administered antibodies, the disease-reducing effect of the anti-IL-6 antibodies could be caused by neutralization of IL-6 activity or by enhancement of IL-6 activity via induction of higher IL-6 levels in the CNS.

Full text

PDF
795

Images in this article

800FIG. 2
on p.800
801FIG. 3
on p.801

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/s0065-2776(08)60532-5. [DOI] [PubMed] [Google Scholar]
  2. Billiau A., Heremans H., Vandekerckhove F., Dijkmans R., Sobis H., Meulepas E., Carton H. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol. 1988 Mar 1;140(5):1506–1510. [PubMed] [Google Scholar]
  3. Black W. J., Munoz J. J., Peacock M. G., Schad P. A., Cowell J. L., Burchall J. J., Lim M., Kent A., Steinman L., Falkow S. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science. 1988 Apr 29;240(4852):656–659. doi: 10.1126/science.2896387. [DOI] [PubMed] [Google Scholar]
  4. Campbell I. L., Abraham C. R., Masliah E., Kemper P., Inglis J. D., Oldstone M. B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10061–10065. doi: 10.1073/pnas.90.21.10061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Campbell I. L., Kay T. W., Oxbrow L., Harrison L. C. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest. 1991 Feb;87(2):739–742. doi: 10.1172/JCI115055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cherwinski H. M., Schumacher J. H., Brown K. D., Mosmann T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987 Nov 1;166(5):1229–1244. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Finck B. K., Chan B., Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug;94(2):585–591. doi: 10.1172/JCI117373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Finkelman F. D., Madden K. B., Morris S. C., Holmes J. M., Boiani N., Katona I. M., Maliszewski C. R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993 Aug 1;151(3):1235–1244. [PubMed] [Google Scholar]
  9. Frei K., Fredrikson S., Fontana A., Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol. 1991 Feb;31(2):147–153. doi: 10.1016/0165-5728(91)90020-8. [DOI] [PubMed] [Google Scholar]
  10. Frei K., Leist T. P., Meager A., Gallo P., Leppert D., Zinkernagel R. M., Fontana A. Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients. J Exp Med. 1988 Jul 1;168(1):449–453. doi: 10.1084/jem.168.1.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frei K., Malipiero U. V., Leist T. P., Zinkernagel R. M., Schwab M. E., Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989 Apr;19(4):689–694. doi: 10.1002/eji.1830190418. [DOI] [PubMed] [Google Scholar]
  12. Gijbels K., Van Damme J., Proost P., Put W., Carton H., Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol. 1990 Jan;20(1):233–235. doi: 10.1002/eji.1830200134. [DOI] [PubMed] [Google Scholar]
  13. Hauser S. L., Doolittle T. H., Lincoln R., Brown R. H., Dinarello C. A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990 Nov;40(11):1735–1739. doi: 10.1212/wnl.40.11.1735. [DOI] [PubMed] [Google Scholar]
  14. Heremans H., Dillen C., Put W., Van Damme J., Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol. 1992 Sep;22(9):2395–2401. doi: 10.1002/eji.1830220932. [DOI] [PubMed] [Google Scholar]
  15. Houssiau F. A., Bukasa K., Sindic C. J., Van Damme J., Van Snick J. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol. 1988 Feb;71(2):320–323. [PMC free article] [PubMed] [Google Scholar]
  16. Houssiau F. A., Devogelaer J. P., Van Damme J., de Deuxchaisnes C. N., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988 Jun;31(6):784–788. doi: 10.1002/art.1780310614. [DOI] [PubMed] [Google Scholar]
  17. Hunter C. A., Abrams J. S., Beaman M. H., Remington J. S. Cytokine mRNA in the central nervous system of SCID mice infected with Toxoplasma gondii: importance of T-cell-independent regulation of resistance to T. gondii. Infect Immun. 1993 Oct;61(10):4038–4044. doi: 10.1128/iai.61.10.4038-4044.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hunter C. A., Jennings F. W., Kennedy P. G., Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Invest. 1992 Nov;67(5):635–642. [PubMed] [Google Scholar]
  19. Libert C., Vink A., Coulie P., Brouckaert P., Everaerdt B., Van Snick J., Fiers W. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol. 1992 Oct;22(10):2625–2630. doi: 10.1002/eji.1830221023. [DOI] [PubMed] [Google Scholar]
  20. Lu Z. Y., Brochier J., Wijdenes J., Brailly H., Bataille R., Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol. 1992 Nov;22(11):2819–2824. doi: 10.1002/eji.1830221110. [DOI] [PubMed] [Google Scholar]
  21. Maimone D., Gregory S., Arnason B. G., Reder A. T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr;32(1):67–74. doi: 10.1016/0165-5728(91)90073-g. [DOI] [PubMed] [Google Scholar]
  22. Martens E., Dillen C., Put W., Heremans H., van Damme J., Billiau A. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur J Immunol. 1993 Aug;23(8):2026–2029. doi: 10.1002/eji.1830230846. [DOI] [PubMed] [Google Scholar]
  23. May L. T., Neta R., Moldawer L. L., Kenney J. S., Patel K., Sehgal P. B. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol. 1993 Sep 15;151(6):3225–3236. [PubMed] [Google Scholar]
  24. Mihara M., Koishihara Y., Fukui H., Yasukawa K., Ohsugi Y. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology. 1991 Sep;74(1):55–59. [PMC free article] [PubMed] [Google Scholar]
  25. Nishimoto N., Yoshizaki K., Eiraku N., Machigashira K., Tagoh H., Ogata A., Kuritani T., Osame M., Kishimoto T. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol Sci. 1990 Jul;97(2-3):183–193. doi: 10.1016/0022-510x(90)90217-b. [DOI] [PubMed] [Google Scholar]
  26. Starnes H. F., Jr, Pearce M. K., Tewari A., Yim J. H., Zou J. C., Abrams J. S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed] [Google Scholar]
  27. Steinman L. Autoimmune disease. Sci Am. 1993 Sep;269(3):106–114. doi: 10.1038/scientificamerican0993-106. [DOI] [PubMed] [Google Scholar]
  28. Suzuki Y., Yang Q., Conley F. K., Abrams J. S., Remington J. S. Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun. 1994 Jul;62(7):2773–2778. doi: 10.1128/iai.62.7.2773-2778.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Swaak A. J., van Rooyen A., Aarden L. A. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989;8(6):263–268. doi: 10.1007/BF00270982. [DOI] [PubMed] [Google Scholar]
  30. Yan H. Q., Banos M. A., Herregodts P., Hooghe R., Hooghe-Peters E. L. Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury. Eur J Immunol. 1992 Nov;22(11):2963–2971. doi: 10.1002/eji.1830221131. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES